rs45517248
Variant summary
Our verdict is Pathogenic. The variant received 16 ACMG points: 16P and 0B. PM1PM2PP3_StrongPP5_Very_Strong
The NM_000548.5(TSC2):c.2549T>C(p.Leu850Pro) variant causes a missense change involving the alteration of a conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Likely pathogenic (★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. L850V) has been classified as Uncertain significance.
Frequency
Consequence
NM_000548.5 missense
Scores
Clinical Significance
Conservation
Publications
- tuberous sclerosisInheritance: AD Classification: DEFINITIVE Submitted by: ClinGen
- tuberous sclerosis 2Inheritance: AD Classification: DEFINITIVE, STRONG Submitted by: PanelApp Australia, Laboratory for Molecular Medicine, Labcorp Genetics (formerly Invitae), G2P, Genomics England PanelApp, Ambry Genetics
- lymphangioleiomyomatosisInheritance: AD Classification: STRONG Submitted by: Genomics England PanelApp
- tuberous sclerosis complexInheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet
Genome browser will be placed here
ACMG classification
Our verdict: Pathogenic. The variant received 16 ACMG points.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes Cov.: 33
GnomAD4 exome Cov.: 33
GnomAD4 genome Cov.: 33
ClinVar
Submissions by phenotype
Tuberous sclerosis 2 Pathogenic:1
In summary, the currently available evidence indicates that the variant is pathogenic, but additional data are needed to prove that conclusively. Therefore, this variant has been classified as Likely Pathogenic. Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt TSC2 protein function. ClinVar contains an entry for this variant (Variation ID: 50077). This variant has been observed in individuals with tuberous sclerosis complex (PMID: 17304050, 25782670; Invitae). This variant is not present in population databases (ExAC no frequency). This sequence change replaces leucine with proline at codon 850 of the TSC2 protein (p.Leu850Pro). The leucine residue is highly conserved and there is a moderate physicochemical difference between leucine and proline. -
Hereditary cancer-predisposing syndrome Pathogenic:1
The p.L850P pathogenic mutation (also known as c.2549T>C), located in coding exon 22 of the TSC2 gene, results from a T to C substitution at nucleotide position 2549. The leucine at codon 850 is replaced by proline, an amino acid with some similar properties. This alteration has been reported as de novo in a patient with tuberous sclerosis complex (Au KS et al, Genet. Med. 2007 Feb; 9(2):88-100). In another study, this mutation was also detected in an individual with tuberous sclerosis complex undergoing everolimus treatment for subependymal giant cell astrocytomas(Kwiatkowski DJ et al, Eur. J. Hum. Genet. 2015 Dec; 23(12):1665-72). Based on the available evidence, p.L850P is classified as a pathogenic mutation. -
Tuberous sclerosis syndrome Other:1
- -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at